SELLAS Life Sciences Group, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

SLS$8.58+1.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

	June 30, 2025	December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$25,297	$13,886
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	4,050	2,341
Total current assets	29,447	16,327
Operating lease right-of-use assets	683	925
Goodwill	1,914	1,914
Deposits and other assets	261	266
Total assets	$32,305	$19,432
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$3,336	$3,500
Accrued expenses and other current liabilities	2,083	5,466
Operating lease liabilities	580	544
Total current liabilities	5,999	9,510
Operating lease liabilities, non-current	157	457
Total liabilities	6,156	9,967
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 100,367,113 and 73,977,459 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	10	7
Additional paid-in capital	286,678	257,583
Accumulated deficit	(260,539)	(248,125)
Total stockholders’ equity	26,149	9,465
Total liabilities and stockholders’ equity	$32,305	$19,432

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.